Bachem Holding AG
SIX:BANB
Intrinsic Value
Bachem Holding AG engages in the provision of peptides and oligonucleotides. [ Read More ]
The intrinsic value of one BANB stock under the Base Case scenario is 78.99 CHF. Compared to the current market price of 80.95 CHF, Bachem Holding AG is Overvalued by 2%.
Valuation Backtest
Bachem Holding AG
Run backtest to discover the historical profit from buying and selling BANB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bachem Holding AG
Current Assets | 841.5m |
Cash & Short-Term Investments | 298.5m |
Receivables | 183.6m |
Other Current Assets | 359.4m |
Non-Current Assets | 841.3m |
PP&E | 814.6m |
Intangibles | 14m |
Other Non-Current Assets | 12.8m |
Current Liabilities | 164.7m |
Accounts Payable | 29.1m |
Accrued Liabilities | 45.8m |
Other Current Liabilities | 89.9m |
Non-Current Liabilities | 197.6m |
Long-Term Debt | 218k |
Other Non-Current Liabilities | 197.4m |
Earnings Waterfall
Bachem Holding AG
Revenue
|
577.3m
CHF
|
Cost of Revenue
|
-400.4m
CHF
|
Gross Profit
|
177m
CHF
|
Operating Expenses
|
-47.6m
CHF
|
Operating Income
|
129.4m
CHF
|
Other Expenses
|
-17.5m
CHF
|
Net Income
|
111.9m
CHF
|
Free Cash Flow Analysis
Bachem Holding AG
BANB Profitability Score
Profitability Due Diligence
Bachem Holding AG's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Bachem Holding AG's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
BANB Solvency Score
Solvency Due Diligence
Bachem Holding AG's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Bachem Holding AG's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BANB Price Targets Summary
Bachem Holding AG
According to Wall Street analysts, the average 1-year price target for BANB is 72.22 CHF with a low forecast of 52.52 CHF and a high forecast of 89.25 CHF.
Shareholder Return
BANB Price
Bachem Holding AG
Average Annual Return | 55.66% |
Standard Deviation of Annual Returns | 87.51% |
Max Drawdown | -70% |
Market Capitalization | 6.1B CHF |
Shares Outstanding | 74 973 645 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 1,639 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one BANB stock under the Base Case scenario is 78.99 CHF.
Compared to the current market price of 80.95 CHF, Bachem Holding AG is Overvalued by 2%.